GC Green Cross Chickenpox Vaccine "Varicellazou" Receives Product Approval in Guatemala

First Approval in Latin America
Accelerating Global Expansion

GC Green Cross announced on March 26 that its chickenpox vaccine, "Varicellazou," has received product approval from the Ministry of Public Health and Social Welfare of Guatemala.

This marks the first time that Varicellazou has obtained product approval in a Central or South American country. The company explained that, in addition to its existing supply through the Pan American Health Organization (PAHO), it plans to accelerate expansion into individual Latin American countries starting with this approval.

A view of the GC Green Cross headquarters in Yongin, Gyeonggi Province. GC Green Cross

Varicellazou is a live vaccine developed by GC Green Cross using its proprietary 'MAV/06' strain. Notably, it is the world's first chickenpox vaccine manufactured with a process that does not use any antibiotics, thereby completely eliminating the risk of adverse reactions caused by antibiotic residues such as kanamycin, neomycin, and erythromycin, and maximizing product safety.

The vaccine's immunogenicity is also excellent. Long-term follow-up clinical trials showed that the seroconversion rate of neutralizing antibodies generated after Varicellazou vaccination was 99-100%, and the persistence of the antibodies was proven to be on par with leading global products.

Recently, Varicellazou was included in the World Health Organization (WHO) position paper, enabling it to receive the same level of international recognition as global vaccines based on the Oka strain, and allowing for interchangeable prescriptions. Through this, the company aims to further expand the scope of Varicellazou's use in the global market.

Lee Jaewoo, Head of Development at GC Green Cross, said, "This approval is significant as it marks the first product registration in Latin America. We will continue to enhance Varicellazou's global presence based on its differentiated product capabilities."

This content was produced with the assistance of AI translation services.